Brenmiller Energy (BNRG) secures $1M Alpha funding with new preferred shares
Rhea-AI Filing Summary
Brenmiller Energy Ltd. completed another funding round with Alpha Capital Anstalt on June 1, 2026, raising $1,000,000 under an existing $25 million securities purchase agreement. The new tranche, called the Sixth Subsequent Funding, continues a series of closings that began in July 2025.
The company issued 1,000 preferred shares with a stated value of $1,000 each, convertible into ordinary shares at $1.67 per share, plus ordinary warrants to buy 598,802 ordinary shares at $14.56 per share for five years. Net proceeds will support general corporate purposes, working capital and commercial TES projects in Europe, the U.S. and the Middle East. The pricing triggered an anti-dilution adjustment, resetting the conversion price of previously issued preferred shares under the agreement to $1.67. After this closing, Brenmiller has 1,895,638 ordinary shares and 3,047 preferred shares outstanding. The securities were issued in a private placement under U.S. exemptions, and the company agreed to register the resale of the ordinary shares underlying the new preferred shares and warrants.
Positive
- None.
Negative
- None.
Insights
Brenmiller raises $1M via preferred stock and warrants, adding future equity overhang.
Brenmiller Energy tapped its existing securities purchase agreement with Alpha Capital Anstalt for another $1,000,000. The structure mixes convertible preferred shares with ordinary warrants, so today’s funding is in cash while future conversion and exercises could expand the ordinary share base.
The June 2026 preferred shares convert at $1.67 per ordinary share, and the associated warrants are struck at $14.56 and last five years. Pricing of this tranche also reset the conversion price of previously issued preferred shares under the same agreement to $1.67, concentrating conversion economics at that level.
As of this closing, the company reports 1,895,638 ordinary shares and 3,047 preferred shares outstanding. The proceeds are earmarked for general corporate purposes, working capital and TES project execution in Europe, the U.S. and the Middle East. Actual dilution will depend on how much of the preferred stock is converted and how many warrants are exercised over time.